TRPC6 and hydrops fetalis: To determine whether any of the TRPC6 variants increased the risk of heart failure in general, we tested for association in an independent sample of 984 patients (males N = 433 and females N = 551) from the Mayo Clinic Biobank consisting of 690 cases with HF from any cause (excluding CRHF) and 282 controls who had previously received anthracycline or trastuzumab without HF.